{"changes":[{"companyHref":"/c/inflam-com","date":"2026-09-25","documentUrl":null,"domain":"inflam.com","fact":"latest round","name":"Inflammasome Therapeutics, Inc.","new":{"amountUsd":13200000,"date":"2026-02-27","lead":null,"type":null},"old":{"amountUsd":13200000,"date":"2026-02-27","lead":null,"type":"seed"},"publisher":"sec-edgar","reason":null,"retrievedAt":"2026-05-05","slug":"inflam-com","status":"attributed","url":"https://whoraisedwhat.com/c/inflam-com"}],"country":"US","description":"Inflammasome Therapeutics develops drug therapies that target inflammasome activation to treat degenerative diseases. The company focuses on patients with ophthalmological conditions like geographic atrophy and neurological disorders such as Alzheimer's and ALS. It pursues a single biological pathway across multiple indications rather than disease-specific mechanisms.","domain":"inflam.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":"inflam","githubStars":null,"industry":"bio","investors":[],"lat":42.330044,"lng":-71.194862,"location":"Newton, MA","name":"Inflammasome Therapeutics, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":13200000,"currency":"USD","date":"2026-02-27","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-05","status":"attributed","url":null},"status":"attributed","type":null,"url":null}],"slug":"inflam-com","sources":[{"fact":"round","publisher":"sec-edgar","retrievedAt":"2026-05-05","status":"attributed","url":null},{"fact":"existence","publisher":"inflam.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://inflam.com"},{"fact":"description","publisher":"inflam.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://inflam.com"}],"stage":null,"techStack":["PHP 8.0.30","Apache HTTP Server","Modernizr","jQuery Migrate","WOW","Bootstrap","jquery 1.12.4","apache"],"totalRaisedUsd":13200000,"updatedAt":"2026-05-05"}